Cedric Munoz, MD
Pulmonary Disease · Boise, IDNPI 1538556337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 44.2% of the total. Reporting peaked in 2024 at $219 and has fallen 72.2% since, to $61 in 2025. That places this record below the midpoint for pulmonary disease clinicians in ID, where the typical reported total is $479.
Across 10 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$134
- Pulmonx Corporation$32
- GSK$31
- Boehringer Ingelheim$26
- Sanofi$25
- Genentech USA, Inc.$24
- plus $31 from 2 others
What the payments were for
- Food & beverage$303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $134 |
| Pulmonx Corporation | 1 | $32 |
| GSK | 2 | $31 |
| Boehringer Ingelheim | 1 | $26 |
| Sanofi | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Electromed, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$115
How this compares
$303 in reported general payments places this provider in the 40th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $207,737 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $195,204 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $61,262 |
| Spiriva RespimatTiotropium Bromide | 72 | $47,006 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $42,880 |
| Advair HfaFluticasone Propion/Salmeterol | 95 | $34,070 |
| Incruse ElliptaUmeclidinium Bromide | 52 | $27,359 |
| Spiriva HandihalerTiotropium Bromide | 50 | $26,955 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $24,775 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $24,425 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $20,532 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,145 |
| XareltoRivaroxaban | 11 | $8,577 |
| EliquisApixaban | 13 | $8,130 |
| DuleraMometasone/Formoterol | 22 | $7,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $31 | $311,716432 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $26 | $288,662143 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $134 | $70,432131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Boise
- Mark RasmusBoise$44K
- Norman EastBoise$11K
- Derek LindermanBoise$7K
- Janat O DonnellBoise$590
- Zahra MathuraBoise$541
- Joshua HolwegerBoise$429
- Rory RamseyBoise$418
- Kathleen SutherlandBoise$224
- Lyndsey TurbowBoise$195
- Ryan BiblerBoise$61
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.